SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
After hours
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverMRK
HealthcareNYSEUSD

Merck & Co.

$001234567890012345678900123456789.0012345678900123456789+10.8%
52w low (est.) $105.90$157.02 52w high (est.)
Peers
Market data
Market cap
$305.12B
52-week range
$76.66 – $130.29
Beta (vs market)
0.20
Sector
Healthcare
Valuation
P/E ratio
34.8x
DCF fair value
$105.00
Margin of safety
-17.7%
Forward P/E
12.9x
PEG ratio
6.22
Dividend yield
2.75%
Quality & efficiency
Moat score
75/100
Return on equity
18.9%
Profit margin
13.6%
Debt / equity
1.07
Growth & analysts
Revenue growth (YoY)
+4.9%
Analyst target
$132.07
Target upside
+3.5%
Analysts covering
27

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Valuation

ValueGrowthProfitHealthIncome43QUALITY
Overall Rating
66
Buy
Buy
Moat Score75
DCF Intrinsic Value
$105.00-17.7% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$305.12B
P/E Ratio
34.8
Dividend Yield
2.75%
Revenue Growth
+4.9%
Profit Margin
13.6%
ROE
18.9%
Debt / Equity
1.07
Beta
0.20
Dividend AristocratsValue
vs Healthcare sector:P/E 35 vs 28 Moat 75 vs 7Yield 2.75% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · MRK